Preclinical CRO niche Invivotek is a small-to-mid sized global preclinical CRO specializing in in vivo small animal studies for drug discovery and early optimization, presenting a clear entry point for partnering on early-stage programs across Immunology, Oncology, Metabolic, and Cardiovascular areas.

Global capability With a facility opened in 2012 and ongoing global CRO positioning, Invivotek can position itself as a reliable, established partner for early safety, efficacy, and biomarker studies, appealing to biotech and pharma clients seeking dedicated preclinical support.

Diversified service mix Offers both custom and standard preclinical services along with in vivo testing, biochemical and molecular techniques, and primary cell culture assays, enabling cross-sell of integrated study packages and biomarker exploration.

Technology stack Leverages cloud and web-based analytics (HubSpot Analytics, AWS), security-focused hosting (Sucuri, X-Content-Type-Options), and standard web tools, highlighting potential for modernized client portals, data integration, and scalable remote reporting.

Growth opportunities Revenue in the low double-digit millions with a lean employee base suggests potential for incremental growth through expanded project capacity, targeted outreach to similarly sized firms, and upsell of biomarker and mechanism-of-action studies to deepen client relationships.